Literature DB >> 23200187

Emerging novel functions of the oxygen-sensing prolyl hydroxylase domain enzymes.

Brian W Wong1, Anna Kuchnio, Ulrike Bruning, Peter Carmeliet.   

Abstract

Oxygen-sensing prolyl hydroxylase domain enzymes (PHDs) target hypoxia-inducible factor (HIF)-α subunits for proteasomal degradation in normoxia through hydroxylation. Recently, novel mechanisms of PHD activation and function have been unveiled. Interestingly, PHD3 can unexpectedly amplify HIF signaling through hydroxylation of the glycolytic enzyme pyruvate kinase (PK) muscle isoform 2 (PKM2). Recent studies have also yielded insight into HIF-independent PHD functions, including the control of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor trafficking in synaptic transmission and the activation of transient receptor potential cation channel member A1 (TRPA1) ion channels by oxygen levels in sensory nerves. Finally, PHD activation has been shown to involve the iron chaperoning function of poly(rC) binding protein (PCBP)1 and the (R)-enantiomer of 2-hydroxyglutarate (2-HG). The intersection of these regulatory pathways and interactions highlight the complexity of PHD regulation and function.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23200187     DOI: 10.1016/j.tibs.2012.10.004

Source DB:  PubMed          Journal:  Trends Biochem Sci        ISSN: 0968-0004            Impact factor:   13.807


  62 in total

1.  The Dawning of a New Day in CKD Anemia Care?

Authors:  Colin R Lenihan; Wolfgang C Winkelmayer
Journal:  J Am Soc Nephrol       Date:  2015-10-22       Impact factor: 10.121

2.  Label-Free Interactome Analysis Revealed an Essential Role of CUL3-KEAP1 Complex in Mediating the Ubiquitination and Degradation of PHD2.

Authors:  Ang Luo; Yue Chen
Journal:  J Proteome Res       Date:  2019-12-06       Impact factor: 4.466

Review 3.  Molecular mechanisms of action and therapeutic uses of pharmacological inhibitors of HIF-prolyl 4-hydroxylases for treatment of ischemic diseases.

Authors:  Vaithinathan Selvaraju; Narasimham L Parinandi; Ram Sudheer Adluri; Joshua W Goldman; Naveed Hussain; Juan A Sanchez; Nilanjana Maulik
Journal:  Antioxid Redox Signal       Date:  2013-10-31       Impact factor: 8.401

Review 4.  Molecular mechanisms of ischemic preconditioning in the kidney.

Authors:  Pinelopi P Kapitsinou; Volker H Haase
Journal:  Am J Physiol Renal Physiol       Date:  2015-08-26

5.  Targeted and Interactome Proteomics Revealed the Role of PHD2 in Regulating BRD4 Proline Hydroxylation.

Authors:  Luke Erber; Ang Luo; Yue Chen
Journal:  Mol Cell Proteomics       Date:  2019-06-25       Impact factor: 5.911

Review 6.  Sirtuins and the Metabolic Hurdles in Cancer.

Authors:  Natalie J German; Marcia C Haigis
Journal:  Curr Biol       Date:  2015-06-29       Impact factor: 10.834

7.  Bone biology: Vessels of rejuvenation.

Authors:  Ferdinand le Noble; Jos le Noble
Journal:  Nature       Date:  2014-03-12       Impact factor: 49.962

Review 8.  Exercise-dependent regulation of the tumour microenvironment.

Authors:  Graeme J Koelwyn; Daniela F Quail; Xiang Zhang; Richard M White; Lee W Jones
Journal:  Nat Rev Cancer       Date:  2017-09-25       Impact factor: 60.716

9.  Short hairpin RNA gene silencing of prolyl hydroxylase-2 with a minicircle vector improves neovascularization of hindlimb ischemia.

Authors:  Maarten A Lijkwan; Alwine A Hellingman; Ernst J Bos; Koen E A van der Bogt; Mei Huang; Nigel G Kooreman; Margreet R de Vries; Hendrika A B Peters; Robert C Robbins; Jaap F Hamming; Paul H A Quax; Joseph C Wu
Journal:  Hum Gene Ther       Date:  2014-01-07       Impact factor: 5.695

Review 10.  Heterogeneity of glycolysis in cancers and therapeutic opportunities.

Authors:  Marc O Warmoes; Jason W Locasale
Journal:  Biochem Pharmacol       Date:  2014-08-02       Impact factor: 5.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.